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Atrial fibrillation (AF) is the most common arrhythmia worldwide and has a significant impact 
on morbidity and mortality.  Additionally, the incidence and prevalence of AF is expected to 
increase in the United States and worldwide over the next few decades.  While the 
pathophysiology concerning the development of AF is not completely understood, multiple 
modifiable, as well as non-modifiable risk factors, for AF development have been discovered.  
The goal of this paper is to provide an overview of the modifiable risk factors that contribute to 
the development and recurrence of AF, in addition to discussing potential lifestyle changes that 
may aid in the prevention and treatment of AF.   
 
Abbreviations: 
A1c=Hemoglobin A1c 
AAD=Anti-arrhythmic drug  
ACEI=Angiotensin-converting enzyme inhibitors  
AF=Atrial fibrillation 
AHI=Apnea/hypopnea index 
ARB=Angiotensin receptor blockers  
BMI=Body mass index 
BP=Blood pressure 
CHD=Coronary heart disease 
CI=Confidence interval 
CPAP=Continuous positive airway pressure 
CRF=Cardiorespiratory fitness  
CV=Cardiovascular 
CVD=Cardiovascular disease 
DBP=Diastolic blood pressure 
HF=Heart failure 
HR=Hazard ratio 
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HTN=Hypertension 
LVEF=Left ventricular ejection fraction 
MET=Metabolic equivalent of task 
MI=Myocardial infarction 
OR=Odds ratio 
OSA=Obstructive sleep apnea 
PA=Physical activity 
RFM=Risk factor management 
RR=Relative risk 
SBP=Systolic blood pressure 
T2DM=Type 2 diabetes mellitus 
US=United States 
VHD=Valvular heart disease 
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Introduction 
 
Atrial fibrillation (AF) is the most common sustained heart rhythm disorder, affecting 
approximately 1% of the world’s population 1 possessing a 25% lifetime risk of AF in the United 
States 
2
. Also, AF has a significant impact on morbidity and mortality, and significantly 
contributes to the disease burden due to symptoms, hospitalizations, and stroke
3,4
.   
The prevalence of AF in the United States is expected to increase from 5.2 million in 2010 to 
12.1 million cases in 2030, owing largely to the expected increase in the incidence of AF from 
1.2 million cases in 2010 to 2.6 million cases in 2030
3
.  Furthermore, the estimated increase in 
the number of elderly individuals in the US over the next few decades most likely also 
contributes to the projected increase in the prevalence of AF.  The age-adjusted prevalence of AF 
is more common in men than in women 
4
 and in Caucasians than in African Americans
5
.  The 
prevalence of AF increases with increasing age, and it has been estimated that approximately 
70% of individuals with AF are between the ages of 65 and 85 
6
.  In addition to the increased 
prevalence of AF with advancing age, the risk of stroke with AF also increases with increasing 
age.  Evidence demonstrates that there is a steep increase in the risk of stroke in patients with AF 
ranging from 1.5% at age 50-59 years to 23.5% at age 80-89 
7
. 
While certain risk factors/conditions, such as increasing age, sleep apnea, type 2 diabetes 
mellitus (T2DM), obesity, alcohol consumption, hypertension (HTN), heart failure (HF), 
coronary heart disease (CHD), chronic excessive strenuous endurance exercise, and valvular 
heart disease (VHD) have been associated with the development of AF, in some patients the 
underlying etiology is unknown 
8,9
 (Table 1).  Regardless, a significant proportion of the known 
AF risk factors are modifiable.  
The goal of this paper is to provide an overview of established, modifiable risk factors for AF.  
Based on this, we will also explore potential lifestyle changes that may potentially decrease the 
risk of AF. 
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Obesity 
 
Multiple studies have shown an association between obesity and AF 
8
.  Evidence suggests that 
large body size during youth, as well as weight gain from age 20 to midlife, are both 
independently associated with the development of AF 
9
.  Although the association between 
obesity and AF is multifactorial, one explanation involves left atrial (LA) size and volume
10
, as 
LA enlargement is a known precursor of AF 
11,12
. Furthermore, obesity has been strongly linked 
to LA size 
13,14
, as well as electrostructural remodeling, which has been associated with 
spontaneous and more persistent AF
15
.  Additionally, data suggests that obesity is an independent 
predictor of left ventricular (LV) diastolic dysfunction, in all age groups from children as early as 
age 9 years to the elderly 
16,17,18
, which is a known risk factor for the development of AF 
19,20
.  
A study published in 2010 demonstrated pericardial fat as another risk factor for incident AF
21
.  
The presence of pericardial fat has been associated with the presence of AF, AF chronicity, and 
symptom burden of AF 
22
.  Furthermore, pericardial fat was also found to be predictive of long-
term AF recurrence after radiofrequency ablation 
23
.  Despite this, weight reduction has been 
associated with a reduction in pericardial adipose tissue
24
. 
A meta-analysis of 16 studies looking at a total of 123,249 individuals demonstrated that obese 
individuals have a 49% increased risk of developing AF compared to non-obese individuals 
(relative risk [RR] 1.49, 95% confidence interval [CI] 1.36-1.64) 
25
. Importantly, a large, 
prospective, community-based observational cohort study demonstrated a 4% increase in AF risk 
per 1-unit increase in body mass index (BMI) in men (95% CI, 1%-7%; P = .02) and in women 
(95% CI, 1%-7%; P = .009)
 26
.  Furthermore, obesity has been associated with the risk of AF 
regardless of the presence or absence of metabolic syndrome
27
.   
In addition to the association between AF and BMI, evidence suggests that obesity may also be a 
risk factor for the progression of paroxysmal AF to permanent AF.   Progression of AF has been 
associated with higher morbidity and mortality. Individuals who progressed from having first-
detected or paroxysmal AF to persistent or permanent AF have been found to have higher rates 
of stroke, transient ischemic attack, myocardial infarction (MI), hospital admission, and death 
when compared to those individuals whose AF had not progressed
28
.  A longitudinal cohort 
study of 3248 patients demonstrated that after adjusting for age and sex, BMI independently 
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predicted the progression to permanent AF (hazard ratio [HR] 1.04, CI 1.03-1.06; P < 0.0001)
 29
. 
Compared with normal BMI (18.5-24.9 kg/m
2
), obesity (30-34.9 kg/m
2
) and severe obesity 
(>or=35 kg/m
2
) were associated with increased risk for progression (HR 1.54,95% CI 1.2-2.0; P 
= 0.0004) and 1.87, 95% CI 1.4-2.5; P < 0.0001, respectively).  
Similarly, an observational population-based cohort study demonstrated lower rates of 
progression of first-detected or paroxysmal AF to persistent or permanent AF in subjects with 
lower BMI.  After adjusting for variables such as age, sex, T2DM, HTN, CHD, cerebral vascular 
accident, VHD, and HF, compared with normal BMI (18.5–24.9 kg/m2), BMI levels of 25.0–
29.9, 30.0–34.9, 35.0–39.9, and ≥ 40.0 kg/m2 were associated with HRs of permanent AF of 1.26 
(95 % CI: 0.92- 1.72); 1.35 (0.96- 1.91); 1.50 (0.97-2.33); and 1.79 (1.13- 2.84) 
30
. 
Fortunately, recent evidence suggests that weight loss with avoidance of weight fluctuations is 
associated with a dose-dependent, long-term reduction in AF burden 
31
.  In fact, a reduction of 
body weight greater than 10% was found to be associated with a 6-fold (95% CI: 3.4-10.3, 
P<0.001) greater probability of arrhythmia-free survival when compared to those individuals 
who only lost 3-9% or <3% of body weight.  However, of note, weight fluctuation of 5% or more 
partially offset the benefits with a 2-fold (95% CI: 1.0-4.3; P=0.02) increased risk of AF 
recurrence.  Weight reduction, in addition to management of risk factors such as HTN, T2DM, 
OSA, alcohol use, and tobacco use has been associated with a greater reduction in AF symptom 
burden and severity when compared to risk factor management alone
32
. 
There is also evidence to suggest that physical activity (PA) is associated with a small reduction 
in the risk of incident AF, even in the presence of excess body weight
33,34
.  Cardiorespiratory 
fitness (CRF) has recently been found to be predictive of arrhythmia-free survival with or 
without rhythm control strategies
35
.  Here, baseline CRF, CRF gains [metabolic equivalent of 
task (METs) gain ≥2], and weight loss were associated with a greater probability of AF-free 
survival.  In fact, METs gain ≥2 in CRF resulted in a 2-fold greater chance of arrhythmia-free 
survival.    
Finally, among overweight patients, risk factor management (RFM), as per the guidelines set by 
the American Heart Association and the American College of Cardiology, has been associated 
with improved long-term success of AF ablation
36
.  In this study, individuals with a BMI ≥27 
kg/m
2
 and ≥1 CHD risk factor were offered RFM in addition to AF ablation.  At follow-up, the 
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RFM group experienced significantly less AF frequency, duration, and symptoms, when 
compared with the control group (P < 0.001). Furthermore, single-procedure drug-unassisted 
arrhythmia-free survival (P < 0.001), as well as multiple procedure arrhythmia free survival (P = 
0.004) was markedly better in RFM patients compared with control subjects.   
 
Obstructive Sleep Apnea (OSA) 
 
The association between OSA and AF is well established and appears to be independent
 
of HTN, 
BMI, and cardiac function
37
.  There have been multiple studies that have demonstrated this 
relationship
38,39
.    
A recent study evaluated 6,841 individuals for OSA at a sleep clinic over a period of 11.9 
years
40
. Age, BMI, HTN, T2DM, VHD, CHD or peripheral artery disease, HF, and chronic 
obstructive pulmonary disease were all univariate predictors of AF (all P<0.001).  After 
multivariable analysis, independent predictors of AF included apnea/hypopnea index (AHI) 
>5/hour, and time with oxygen saturation less than 90%. 
Although the exact mechanism behind the relationship between OSA and AF is not fully 
understood, a few mechanisms have been proposed.  A recent study suggested that atrial 
remodeling associated with OSA may be responsible for the development of AF secondary to 
reduction in voltage, site-specific and widespread conduction abnormalities, and longer sinus 
node recovery
41
.  OSA-related stretch in the atrium and pulmonary veins are often associated 
with increases in transmural pressure that may result in atrial and pulmonary vein dilation and 
subsequently AF 
42
.  It has also been suggested that negative tracheal pressure during obstructive 
events is a strong trigger for AF secondary to enhanced vagal activation 
43
.  Other theories on the 
relationship between OSA and AF include higher levels of serum amyloid 
44
, and elevated levels 
of inflammatory markers such as C-reactive protein 
45
 and interleukin-6 
46
   
Moreover, in addition to the increased risk of AF in patients with OSA, a recent study has shown 
that AF patients with severe OSA are less likely to respond to anti-arrhythmic drug (AAD) 
therapy compared to patients with milder forms of OSA 
47
. The study evaluated the impact of 
OSA severity on the treatment of patients with AF using AADs. They included 61 patients with 
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symptomatic AF who were treated with AADs and underwent overnight polysomnography. They 
found that individuals with severe OSA were less likely to respond to AADs when compared to 
those with milder OSA (39% vs 70%, P = 0.02).  Furthermore, non-responders had higher AHI 
indexes than responders (34 ± 25 vs 22 ± 18 events/hour, P = 0.05).  There was no difference 
between these groups with respect to minimum oxygen saturation or percentage of time spent in 
rapid eye movement sleep. 
Additionally, a recent meta-analysis, which included 6 studies of 3,995 patients, suggests that 
patients with OSA have a greater risk of recurrence of AF even after pulmonary vein isolation 
48
. 
Patients with OSA had a 25% greater risk of AF recurrence after catheter ablation than those 
without OSA (RR 1.25, 95% CI 1.08 to 1.45, P = 0.003). Furthermore, OSA diagnosed using 
polysomnography was a much stronger predictor of AF recurrence (RR 1.40, 95% CI 1.16 to 
1.68, P = 0.0004) compared to OSA diagnosed using the Berlin questionnaire (RR 1.07, 95% CI 
0.91 to 1.27, P = 0.39).  In fact, the presence of severe OSA has been shown to be an 
independent risk factor for AF ablation failure 
49
.   
Fortunately, evidence suggests that OSA patients treated with continuous positive airway 
pressure (CPAP) have lower rates of AF recurrence and better heart rate control when compared 
to untreated patients
50
.  Patients with OSA on CPAP treatment were also less likely to progress 
to more permanent forms of AF compared with patients without CPAP 
51
.   
 
Finally, evidence suggests that patients with untreated OSA have a higher rate of recurrence of 
AF after ablation when compared to CPAP users
52
.  A meta-analysis of 5 studies involving 3,743 
individuals with AF demonstrated that patients with OSA had a 31% greater risk of AF 
recurrence after catheter ablation when compared to those individuals without OSA (RR = 
1.31)
53
.  This risk increased by 57% among OSA patients without CPAP therapy (RR = 1.57).  
More importantly, CPAP users had a risk of AF recurrence similar to that of patients without 
OSA (RR = 1.25, P = 0.37).  Furthermore, CPAP utilization in the setting of OSA is associated 
with a reduction in AF recurrence irrespective of whether they undergo PVI
54
.    
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Hypertension 
 
 
HTN is the most common cardiovascular (CV) disorder, and is a well-established modifiable risk 
factor for AF development 
55,56,57
.  There is evidence to suggest a correlation between systolic 
blood pressure (BP;SBP) and incident AF 
58,59
.  Data from the Women's Health Study suggests 
that among women, SBP, rather than diastolic BP (DBP), was a better predictor of incident AF 
60
. Here, multivariable-adjusted HR for SBP categories (<120, 120 to 129, 130 to 139, 140 to 
159, and > or =160 mm Hg) were 1.0, 1.14 (95% CI, 0.89 - 1.46), 1.37 (95% CI, 1.07 - 1.76), 
1.71 (95% CI, 1.33 - 2.21), and 2.21 (95% CI, 1.45 - 3.36; P for trend <0.0001).  By comparison, 
the adjusted HR for  DBP categories (<65, 65 to 74, 75 to 84, 85 to 89, 90 to 94, and > or =95 
mm Hg) were 1.0, 1.12 (95% CI, 0.82 - 1.52), 1.13 (95% CI, 0.83 - 1.52), 1.30 (95% CI, 0.89 -
1.88), 1.50 (95% CI, 1.01 - 1.88), and 1.54 (95% CI, 0.75 - 3.14) (P for trend=0.026). 
 
The relationship between BP and AF may also be present among individuals with upper normal 
BP.  A Norwegian study of 2014 healthy males followed for 35 years demonstrated that men 
with baseline  SBP ≥140 mm Hg had a 1.60-fold (95% CI 1.15- 2.21) risk of developing AF, and 
those with upper normal  SBP 128 to 138 mm Hg had a 1.50-fold (95% CI 1.10- 2.03) risk of 
AF, when compared to those individuals with SBP <128 mm Hg
61
. Furthermore, in this cohort, 
baseline  DBP ≥80 mm Hg increased the risk of incident AF 1.79-fold (95% CI 1.28 - 2.59) 
compared with DBP <80 mm Hg. 
Despite this, there are no clear guidelines recommending a target BP to reduce the risk of AF in 
patients with HTN.  While there is evidence to suggest that elevated  SBP increases the risk of 
developing AF, tightly controlled  SBP (<120 mmHg) has also been shown to increase the risk of 
incident AF.  These findings were observed in a case-control study that demonstrated that the 
odds ratio (OR) and CI for incident AF were 1.99 (1.10 -3.62), 1.19 (0.78 - 1.81), 1.40 (0.93 - 
2.09), 2.02 (1.30 - 3.15), 2.27 (1.31 - 3.93), and 1.84 (0.89 - 3.80) among those individuals who 
had an average achieved  SBP (with pharmacologic treatment) of <120, 130-139, 140-149, 150-
159, 160-169, and > or =170 mm Hg, respectively
62
.  Furthermore, post-hoc analysis from the 
Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) trial 
demonstrated a U-shaped relationship between BP and all-cause mortality among patients with 
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AF who were being treated for HTN.  Here, the all-cause mortality increased when BP was 
reduced to < 110/60 mmHg 
63
.   
Furthermore, pooled analysis from the AFFIRM and AF and Congestive HF trial (AF-CHF) 
trials demonstrated that elevated systolic BP was associated with increased rates of AF 
recurrence and overall AF burden among individuals with LV ejection fraction (LVEF) ≤40%64.  
Among these individuals, the recurrence rate of AF was higher among those with an SBP >140 
mmHg when compared to those individuals with SBP 120-140 mmHg (HR 1.47; 95% CI 1.12-
1.93, P = 0.005).  In fact, among patients with LVEF ≤40%, the adjusted mean proportion of 
time spent in AF was 17.2% if SBP was <120 mmHg, 15.4% for SBP 120-140 mmHg, and 
24.0% for SBP >140 mmHg (P = 0.025). 
Although the underlying pathophysiology is not fully understood, the development of AF among 
patients is most likely related to atrial remodeling secondary to activity from the renin-
angiotensin system
65
.  Despite this, the data regarding the use of angiotensin-converting enzyme 
inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in the prevention or treatment of 
AF is conflicting and, as a result, these classes of medications are not routinely used in the 
management of AF.   
A beneficial effect of ARBs on the development of new-onset AF was demonstrated in two post-
hoc analyses of two large hypertension [Losartan Intervention For End Point Reduction in 
Hypertension trial (LIFE) and Valsartan Antihypertensive Long-term Use Evaluation Trial 
(VALUE)] trials.  In the LIFE study, new-onset AF occurred in 6.6 per 1000 person years among 
patients randomized to losartan compared with 10.1 per 1000 person years among those 
randomized to atenolol (RR 0.67, 95% CI 0.55 - 0.83, P < 0.001).  Despite similar BP reduction 
with both drugs, patients receiving losartan tended to stay in sinus rhythm longer (1,809 +/- 225 
vs. 1,709 +/- 254 days from baseline, P = 0.057) than those receiving atenolol. 
Similarly, data from the VALUE trial demonstrated that the incidence of new-onset AF was 
3.67% with valsartan compared to 4.34% with amlodipine (unadjusted HR 0.843, 95% CI 0.713 
- 0.997, P = 0.0455) 
66
. Additionally, the incidence of persistent AF was 1.35% in the valsartan 
group compared to 1.97% in the amlodipine group (unadjusted HR 0.683, 95% CI 0.525 to 
0.889, P = 0.0046).  
A large meta-analysis of 11 studies and 56,308 patients demonstrated that ACEI’s and ARB’s 
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decreased relative risk of AF by 28% (95% CI 15% - 40%, P = 0.0002) 
67
.  However, this 
reduction in AF was limited to patients with LV systolic dysfunction and LV hypertrophy.  No 
significant reduction in AF was seen in patients with HTN.    
Conversely, other studies were unable to demonstrate any beneficial effect of ACEI’s and ARB’s 
in the prevention of AF.  A small meta-analysis of four ACEI studies consisting of 355 patients, 
and six ARB studies consisting of 4040 patients demonstrated that while ACEI were statistically 
significant in preventing AF recurrence, ARB’s did not show any effect in the prevention of AF 
68
. However, the studies were individually very small and did not have a strong follow-up 
algorithm to recognize AF episodes. 
The GISSI-AF trial was also unable to demonstrate any reduction in the incidence of AF 
between the valsartan group (51.4% AF recurrences in a 12-month follow-up) and the placebo 
group (52.1% of AF in a 12-month follow-up, P = non significant)69.   
 
Diabetes Mellitus 
 
 
Diabetes mellitus, more commonly T2DM, and AF often coexist with up to 20% of AF patients 
also having T2DM
70
.  There have been multiple trials that have demonstrated the relationship 
between T2DM and AF.  Regardless, this relationship between AF and T2DM is still 
controversial and various studies have demonstrated conflicting results.  A large meta-analysis of 
seven prospective cohort studies and four case control studies involving 108,703 cases of AF 
among 1,686,097 individuals demonstrated a 40% increased risk of AF among T2DM patients 
compared to those individuals without T2DM 
71
.  Similarly, data from an observational cohort 
study demonstrated that AF prevalence was greater among those patients with T2DM (3.6 vs. 
2.5%, P < 0.0001) 
72
.  The incidence of AF development among patients with T2DM over 7.2 
years was 9.1 per 1,000 person-years (95% CI 8.6-9.7) compared with 6.6 (95% CI 6.2-7.1) 
among patients without T2DM. After adjusting for multiple risk factors, T2DM remained 
associated with a 26% increased risk of AF among women (HR 1.26 95% CI 1.08-1.46) but was 
not a statistically significant factor among men (1.09, 95% CI 0.96-1.24). 
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Data from the VALUE trial population also demonstrated an association between T2DM and 
AF
73
.  Here, of the 15,245 participants in the trial, 5,250 patients had T2DM at baseline.  Over 
the 4.2 year follow-up period, 1,298 of the initially non-diabetic patients developed T2DM, and 
551 patients developed new-onset AF over this time period. The study demonstrated that patients 
with new-onset T2DM had significantly higher rates of new-onset AF (HR 1.49, 95% CI 1.14 - 
1.94, P = 0.0031) compared to patients without T2DM.  
 
A recent population-based case-control study of approximately 3600 participants suggested that 
persistent, uncontrolled T2DM, based on hemoglobin A1c(A1c), might pose a cumulative risk on 
the initiation of AF
74
.  Among the patients with AF (1,410 patients), 252 (17.9%) had T2DM 
compared to 311 (14.1%) of the controls (2,203 patients). The adjusted OR for AF was 1.40 
(95% CI 1.15 to 1.71) for people with T2DM compared to those without T2DM. It was also 
observed that the risk of developing AF was 3% higher for each additional year of persistent 
T2DM (95% CI 1.0 to 6.0). Furthermore, the study demonstrated that compared to patients 
without T2DM, the OR for AF among those patients with T2DM increased with increasing  A1c 
levels. Patients with an average A1c <or=7 was 1.06 (95% CI 0.74 to1.51); for A1c >7 but 
<or=8, 1.48 (1.09 to 2.01); for A1c >8 but <or=9, 1.46 (1.02 to 2.08); and for A1c >9, 1.96 (1.22 
to 3.14).  This suggests that strict long-term glucose control may play a significant role in 
decreasing incidence of new-onset AF. 
 
Despite the evidence presented, the correlation between T2DM and AF is disputable.  Data from 
the Framingham Heart Study, published in 2009, were unable show any statistically significant 
association between the AF and T2DM
75
.  The presence of AF among patients with T2DM and 
HTN was evaluated in another study consisting of 1739 individuals (798 men, 941 women)
76
.  
Patients were categorized as either having HTN (n = 597), both HTN and T2DM (n = 171), or 
only T2DM (n = 147). The adjusted OR and 95% CI were: 0.7 (0.30-1.5) among the patients 
with HTN only, 3.3 (1.6-6.7) among those patients with HTN and T2DM, and 2.0 (0.9-4.7) 
among patients with T2DM only; suggesting no statistically significant association between 
T2DM and AF.     
 
Based on these data, the presence and duration of T2DM contribute to the development of AF.  
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Furthermore, as mentioned above, patients with A1c >7.0 appear to be at a higher risk of AF than 
those with A1c < 7.0.  Therefore, strict overall blood glucose control to achieve an A1c <7.0 
would seem advisable.     
 
 
Alcohol Consumption 
 
“Holiday heart syndrome” is one of the oldest descriptions of alcohol-induced arrhythmias77. It 
was first described in generally healthy individuals who presented after holidays or weekends 
involving heavy alcohol consumption.  In these instances, conversion to normal sinus rhythm 
occurred in approximately 24 hours
78
.  Since then, there have been multiple studies that have 
demonstrated the arrhythmogenic properties of alcohol consumption
79
 and a positive relationship 
between high alcohol consumption and AF
80
.  The Copenhagen City Heart Study concluded that 
among men, consumption of ≥35 alcoholic drinks per week was associated with an increased risk 
of AF development (HR of 1.45;95% CI 1.02- 2.04) 
81
.  Furthermore, the study concluded that 
approximately 5% of all cases of AF are related to alcohol consumption.  A meta-analysis 
published in 2010 demonstrated that compared to nondrinkers, women consuming 24, 60 and 
120 grams of alcohol daily (approximately 2,5, and 10 drinks per day, respectively) had a RR of 
1.07 (95% CI: 1.04–1.10), 1.42 (95% CI: 1.23–1.64) and 2.02 (95% CI: 1.60–2.97), respectively 
82
. Similarly, the corresponding RR were 1.08 (95% CI: 1.04–1.11), 1.44 (95% CI: 1.23–1.69) 
and 2.09(95% CI: 1.52–2.86) among men.  
A large prospective study followed 79,019 Swedish men and women over a 12 year period to 
assess the association between low to moderate alcohol consumption and AF
83
.  Compared to 
those individuals who consumed <1 drink/week (12 g alcohol/drink), the multivariable RR of AF 
were 1.01 (95% CI: 0.94 - 1.09) for 1 to 6 drinks/week, 1.07 (95% CI: 0.98 - 1.17) for 7 to 14 
drinks/week, 1.14 (95% CI: 1.01 - 1.28) for 15 to 21 drinks/week, and 1.39 (95% CI: 1.22 - 1.58) 
for >21 drinks/week  This association did not differ by sex (P for interaction = 0.74).  This 
suggests that even moderate alcohol consumption is a risk factor for AF.    
Conversely, while the Framingham Study demonstrated a significantly increased risk of AF 
among individuals who consumed >36 grams of alcohol/day (approximately >3 drinks per day), 
there was no significant association between moderate alcohol consumption and the risk of AF
84
.   
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Similarly, another large study that evaluated the risk of alcohol induced AF specifically in 
women 
85
 found that consumption of 2 or fewer alcoholic drinks per day was not associated with 
an increased risk of AF. However, consumption of 2 or more drinks per day was associated with 
a small but statistically significantly increased risk of AF (HR 1.60; 95% CI, 1.13-2.25).   
Lowering alcohol intake may be effective in the prevention of AF.  While most of the data 
correlates high alcohol consumption with AF, there is also evidence to suggest that moderate 
alcohol consumption also may be associated with an increased risk of AF.  Limiting alcohol 
consumption to ≤ 1-2 drinks per day may be beneficial in AF prevention.   
 
Physical Activity 
 
Many studies have demonstrated the beneficial effects of exercise/PA on CV health 
86,87
.  
Despite this, the incidence of AF appears to be increased among elite athletes, and multiple small 
studies have demonstrated a relationship between AF and vigorous PA, related to either long-
term endurance sport participation or occupational PA
88,89,90
.   
 
Regardless of the relationship between high intensity PA and AF, recent data suggests a 
nonlinear relationship between higher levels of CRF and AF
91
.   In one study, 1,950 middle-aged 
males were followed over a 19.5-year period to evaluate the relationship between CRF and 
incident AF.   Here, the rates of incident AF per 1000 person-years of follow-up were 11.5 (95% 
CI 9.4-14.0) in the first quartile of CRF, to 9.1 (95% CI 7.4-11.2) in the second quartile, 5.7 
(95% CI 4.4-7.4) for the third quartile, and 6.3 (95% CI 5.0-8.0) for the fourth quartile 
suggesting a modest increase in AF incidence in individuals with very high levels of CRF.  
While the association of high intensity PA and AF is not fully understood, possible mechanisms 
may involve acute fluxes in catecholamines and autonomic tone, atrial stretch, and RV 
cardiomyopathy 
92,93
.   
 
Another recent study evaluated the effects of PA on AF among 36,513 Swedish women over a 
12 year period
94
.   Among this cohort of women, the risk of AF decreased with increasing levels 
of leisure-time PA (RR 0.85, 95% CI 0.75 - 0.95 for ≥4 h/week vs <1 h/week) and 
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walking/bicycling (RR 0.81, 95% CI 0.72 - 0.92, for ≥40 min/day vs almost never), suggesting 
that moderate PA was associated with a decreased risk of AF.  
 
The association between endurance sports and AF was first described in a longitudinal, 
prospective study
95
 in a series of orienteers (athletes who participate in vigorous exercise) over a 
10-year period.  Among the orienteers, they observed a RR of 5.5 (95% CI 1.3 -24.4) for AF 
when compared to healthy age-matched controls.  The rate of AF among the orienteers was 5.3% 
(95% CI 2.8% - 9.0%)) compared to 0.9% (95% CI 0.1%- 3.4%) among the control group.  They 
concluded that long-term vigorous exercise in men was associated with an increased risk of AF.  
 
These findings were collaborated by many subsequent studies.  A study of 160 participants (51 
subjects with lone AF and 109 controls from the general population) demonstrated that 
participation in over 1500 lifetime hours of sports was associated with an increased risk of lone 
AF (OR 2.87; 95% CI: 1.20 - 6.91) when compared to the controls selected from the general 
population 
96
.  Another study of 134 former Swiss professional cyclists demonstrated that these 
athletes with a very high number of years competing in bicycle races had a higher incidence of 
AF or atrial flutter compared to the control group (P = 0.028) 
97
.  Fortunately, this risk of AF 
appears to resolve with moderation of exercise dose and detraining which may be secondary to 
normalization of the autonomic tone
98
.   
 
However, a meta-analysis of 19 studies consisting of 511,503 individuals demonstrated no 
association between intensive PA and AF (RR 1.00 95% CI 0.82-1.22).  In fact, there was no 
correlation between increased time spent on PA and AF (RR 0.95 95% CI 0.72-1.26).  Based on 
the data from this meta-analysis, in addition to the beneficial effects of PA on CV health and AF 
as stated above, patients should be encouraged to exercise and remain physically active, but 
perhaps avoid chronic excessive endurance exercise such as marathons, ultra-marathons, and 
Ironman-distance triathlons, especially for individuals over age 50.    
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Caffeine 
 
There is evidence to suggest that caffeine consumption in moderate amounts may actually 
decrease the occurrence of AF 
99,100
.  A recent meta-analysis of 6 prospective cohort studies with 
228,465 individuals showed a trend towards caffeine consumption being associated with AF risk 
reduction (RR, 0.90; 95% CI, 0.81-1.01; P = 0.07) 
101
.  However, subgroup analysis 
demonstrated an 11% reduction in AF risk with low doses of caffeine consumption (P= 0.032) 
and a 16% reduction for high doses (P= 0.002).  Furthermore, for every 300 mg/d increment in 
habitual caffeine intake, the incidence of AF decreased by 6% in dose-response meta-analysis.   
 
Another meta-analysis of 7 observational studies with 115,993 subjects showed that in addition 
to no association between caffeine exposure and risk of AF (OR 0.92, 95% CI 0.82 to 1.04), 
pooled results showed a 13% reduction in AF risk (OR 0.87; 95% CI 0.80 - 0.94). Furthermore, 
low-dose caffeine exposure showed OR 0.85 (95% CI 0.78 - 92) without significant differences 
in other dosage strata. 
 
Despite this evidence showing a negative correlation between AF and caffeine intake, 
individuals with AF are occasionally advised to avoid drinking tea and coffee
102,103
.  Based on 
the data presented above, caffeine intake should not be discouraged among patients with the sole 
purpose of AF prevention (Figure 1).  In fact, low to moderate amounts of daily caffeine 
consumption may potentially decrease the risk of AF, though this response is quite variable and 
thus the advice regarding caffeine intake should be individualized to each patient.     
 
 
Conclusion 
 
AF is the most common sustained heart rhythm disorder worldwide.  Despite our incomplete 
understanding of this disease process, decades of research have discovered multiple modifiable, 
as well as non-modifiable risk factors responsible for AF development.  Through proper medical 
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management and lifestyle changes, the impact of these modifiable risk factors, including obesity, 
OSA, HTN, T2DM, and alcohol consumption, AF risk may be reduced substantially.  
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Figure Legend 
1. Potential risk factor modifications to reduce the incidence and prevalence of atrial 
fibrillation.  AF= atrial fibrillation, HbA1c= hemoglobin A1c, SBP=systolic blood 
pressure 
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Sleep Apnea Hypertension
Risk Factors and Potential Lifestyle
Modifications to Reduce AF
Weight Loss 
> 10%
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Limit Alcohol 
Consumption to
< 2 drinks/day
Blood Glucose 
Control –
 HbA1c < 7.0
Continuous 
Positive Airway 
Pressure 
Utilization
Maintain SBP 
<140 mmHg 
but >110 mmHg
